Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aditxt Inc ADTX

Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women’s health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.


NDAQ:ADTX - Post by User

<< Previous
Bullboard Posts
Next >>
User Avatar Image
(1441)
•••
  • IseneschalX
Comment by Iseneschalon Dec 12, 2023 9:32am
65 Views
Post# 35779631

RE:ADTX...... Wait for the fireworks...u ain't seen nothin yet

RE:ADTX...... Wait for the fireworks...u ain't seen nothin yet
Merry Xmas comes early


Yeeha!!!!
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities